Navigation Links
Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
Date:12/9/2008

SAN FRANCISCO, Dec. 9 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced preliminary data from its recently completed multi-center, open-label, ascending-dose Phase 1b clinical study of CD-NP, a novel chimeric natriuretic peptide, in patients with heart failure. Results of this study showed:

  • CD-NP was well tolerated at doses of up to 20 ng/kg/min
  • Blood pressure effects were dose dependent and well characterized
  • CD-NP demonstrated diuretic effects comparable to furosemide
  • CD-NP produced statistically significant changes on biomarkers consistent with enhanced renal function

These positive results are supportive of further study to fully validate proof-of-concept of CD-NP in a Phase 2b clinical trial planned to begin in 2009.

About the Study

The objectives of the Phase 1b study were to establish the maximum tolerated dose (MTD) and to assess the pharmacodynamic effects of CD-NP on blood pressure and renal function in stable heart failure patients. Patients with NYHA Class II or Class III heart failure, ejection fraction <40% and current signs of fluid overload were included in the study. In this dose escalation trial, four cohorts were administered a single 24-hour infusion of CD-NP at a dose of either 3 (n=6), 10 (n=6), 20(n=6) or 30 ng/kg/min (n=2). During the infusion of CD-NP, furosemide and vasoactive therapies were withheld.

Effects on Blood Pressure

The effects on blood pressure were dose-dependent. During a 24-hour infusion of CD-NP at doses of 3, 10 and 20 ng/kg/min, mean reductions in Mean Arterial Pressure were 2.2, 8.9 and 13.2 mmHg respectively.

CD-NP was well-tolerated at dos
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
2. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
3. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
4. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
8. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
9. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
10. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
11. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014 /CNW/ - Aequus Pharmaceuticals Inc. ... that it has closed a brokered private placement ... approximately C$3.7 million.  Cormark Securities Inc. and Clarus ... Brokered Offering for a syndicate of agents that ... Corp. (collectively the "Agents"). Concurrently with the Brokered ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood ... sponsor of the 10th Annual World Stem Cell Summit, the ... stakeholders. The 2014 World Stem Cell Summit will be held ... Antonio, Texas . The World ... development of lifesaving cures and therapies, convening the most prominent ...
(Date:11/18/2014)... 17, 2014 pH measurement and control ... the pharmaceutical, chemical, and food and beverage industries. But ... and how do pH sensors work? METTLER TOLEDO has ... in process industries with these questions and more. , ... in the process industries. The actual sensor, the pH ...
(Date:11/18/2014)... Atlanta, Georgia (PRWEB) November 18, 2014 ... Automotive (Melbourne, Australia) recently formed a partnership with ... University, Swinburne University of Technology, and the USDA’s ... structural components reinforced with nanocellulose. Nanocellulose is a ... The goal of the project is to replace ...
Breaking Biology Technology:Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3pH Guide from METTLER TOLEDO Explains Measurement, Theory and Practice of pH Applications 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3
... McCormick School of Engineering and Applied Science at Northwestern ... of probe used in atomic force microscopy (AFM), which ... Using diamond, researchers made a much more durable ... are typically used in AFM to gather information from ...
... SEATTLE, Nov. 11 Dendreon Corporation (Nasdaq: DNDN ) ... Revenue for the third quarter of 2009 was $25,000 compared ... for the nine months ended September 30, 2009 was $80,000 ... 2008. , Dendreon,s total operating expenses for the third ...
... HAIKOU CITY, China, Nov. 11 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, ... specialty pharmaceutical products in China, today announced financial,results for the ... Third Quarter 2009 Financial Highlights, -- ... the, third quarter of ...
Cached Biology Technology:New nanocrystalline diamond probes overcome wear 2Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 2Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 3Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 4Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 5Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 6China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 2China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 3China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 4China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 5China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 6China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 7China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 8China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates 9
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
(Date:11/6/2014)... deaths occur because of metastasis, yet progress in ... slow. , "It,s been particularly challenging to design ... research fellow in systems biology at Harvard Medical ... until after they,ve already metastasized." , Gujral and ... should help researchers better understand how metastasis begins. ...
(Date:11/5/2014)... – Kelly Redmond has dedicated his career to ... to a general audience. , As deputy director ... Center at Nevada,s Desert Research Institute, Redmond has ... management, application and dissemination of climate data to ... Fall Meeting in San Francisco on December 15-19, ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... scientists at UCLA showed for the first time that ... into electrically active motor neurons, a discovery that may ... the motor neurons derived from the iPS cells appeared ... derived from human embryonic stem cells, although further testing ...
... WASHINGTONResearchers are exploring extreme conditions for life in a ... 20 meters (66 feet) below the surface of Lake ... peculiar geological formationssinkholes made by water dissolving parts of ... typical of the huge freshwater lake are rarely to ...
... , McGill University chemistry professor Chao-Jun (C.J.) Li is ... chemistry, an entirely new approach to the science which eschews ... substances like water and new ways of making molecules. ... significant, but following the road less travelled is also paying ...
Cached Biology News:UCLA stem cells scientists make electrically active motor neurons from iPS cells 2Great Lake's sinkholes host exotic ecosystems 2Peptides-on-demand: McGill researcher's radical new green chemistry makes the impossible possible 2
... CHEMICON's In Vitro Osteogenesis Assay Kit contains ... to a mature osteoblastic lineage, as determined ... kit provides all the necessary reagents and ... standard plate reader. This product is useful ...
... ATP-Gamma-S binds to ATP-binding proteins. To ... FL fluorophore was linked through the ... its potential use for binding studies ... an important new substrate for Fhit ...
... offers precise 96 and 384-well transfers in ... and 200ul disposable tips, the 96 channel ... precision across a volume range from 1-200uls. ... positions that enable indexing into 384 well ...
... contain 60 rabbit tissue samples arrayed on Superfrost ... slides and 1 hematoxylin and eosin (H&E) stained ... different tissues from 4 rabbit organisms, for a ... tissue sample (or core) is 1.5 mm in ...
Biology Products: